• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Medicare Coverage of Aducanumab - Implications for State Budgets.

作者信息

Sachs Rachel E, Bagley Nicholas

机构信息

From Washington University School of Law, St. Louis (R.E.S.); and University of Michigan Law School, Ann Arbor (N.B.).

出版信息

N Engl J Med. 2021 Nov 25;385(22):2019-2021. doi: 10.1056/NEJMp2115297. Epub 2021 Nov 20.

DOI:10.1056/NEJMp2115297
PMID:34797617
Abstract
摘要

相似文献

1
Medicare Coverage of Aducanumab - Implications for State Budgets.阿杜卡奴单抗的医疗保险覆盖范围——对州预算的影响。
N Engl J Med. 2021 Nov 25;385(22):2019-2021. doi: 10.1056/NEJMp2115297. Epub 2021 Nov 20.
2
Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.为什么阿杜卡努单抗每位患者定价56000美元？药物定价改革的经验教训。
N Engl J Med. 2021 Nov 25;385(22):2017-2019. doi: 10.1056/NEJMp2113679. Epub 2021 Nov 20.
3
Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?美国医疗保险和医疗补助服务中心（CMS）会在阿杜卡努单抗获得美国食品药品监督管理局（FDA）批准后，认定其对阿尔茨海默病的治疗合理且必要吗？
JAMA. 2021 Aug 3;326(5):383-384. doi: 10.1001/jama.2021.11768.
4
Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.医疗保险不应涵盖阿杜卡奴单抗作为阿尔茨海默病的治疗手段。
Ann Neurol. 2021 Sep;90(3):331-333. doi: 10.1002/ana.26167. Epub 2021 Aug 10.
5
The APTA electrical stimulation lawsuit and its aftermath. American Physical Therapy Association.美国物理治疗协会的电刺激诉讼及其后果。美国物理治疗协会。
Adv Wound Care. 1999 Nov-Dec;12(9):472-5.
6
State Medicaid prescription drug expenditures for Medicare-Medicaid dual eligibles: estimates of Medicaid savings and federal expenditures resulting from expanded Medicare prescription coverage.针对医疗保险 - 医疗补助双重资格者的州医疗补助处方药支出：扩大医疗保险处方药覆盖范围带来的医疗补助节省及联邦支出估算。
Issue Brief (Commonw Fund). 2003 Apr(627):1-12.
7
Commentary on payment and reimbursement issues affecting the marketing of drugs, medical devices, and biologics, with emphasis on the anti-kickback statute and Stark II.
Food Drug Law J. 1997;52(1):99-108.
8
Perspectives. IGT ban, flexibility on tap for Medicaid, but what for Medicare?
Med Health. 2005 Mar;59(6 Spec no.):1, 7-8.
9
Medicare changes: fairer payments, delay in practice expenses.
Minn Med. 1997 Sep;80(9):35.
10
One pill, many prices: variation in prescription drug prices in selected government programs.一粒药，多个价格：特定政府项目中处方药价格的差异
Issue Brief George Wash Univ Natl Health Policy Forum. 2005 Aug 29(807):1-20.

引用本文的文献

1
The Next Generation of Payment Reforms for Population Health - An Actionable Agenda for 2035 Informed by Past Gains and Ongoing Lessons.支付改革推动人群健康的新纪元——2035 年行动计划，基于既往成就与持续经验教训
Milbank Q. 2023 Apr;101(S1):866-892. doi: 10.1111/1468-0009.12632.
2
Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society.临床前阿尔茨海默病生物标志物披露对美国政策和社会的影响。
Alzheimers Dement (Amst). 2022 Aug 25;14(1):e12339. doi: 10.1002/dad2.12339. eCollection 2022.
3
Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab.
追求加速审批的合理性：预测并避免下一个 aducanumab。
Drugs Aging. 2022 Jun;39(6):389-400. doi: 10.1007/s40266-022-00949-8. Epub 2022 Jun 13.
4
Expedited regulatory product approval in the time of COVID-19.在新冠疫情期间加快监管产品审批
Ocul Surf. 2022 Oct;26:345-348. doi: 10.1016/j.jtos.2022.05.007. Epub 2022 May 28.